# Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes

> **NCT02686281** · PHASE1 · TERMINATED · sponsor: **Genmedica Therapeutics S.L.** · enrollment: 19 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GMC-252-L-Lysine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02686281
- **Lead sponsor:** Genmedica Therapeutics S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2013-07
- **Final completion:** 2014-04
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Business reason
- **Last updated:** 2016-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02686281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02686281, "Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02686281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*